To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
February 2019

Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis

Vol: 8| Issue: 2| Number:42| ISSN#: 2564-2537
Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials

Climacteric. 2018 Apr;21(2):189-195

Contributing Authors:
B Zhang W Zhang J Wu Y Cao S Zhang Y Liu Z Li Q Tang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Six randomized controlled trials were included in this meta-analysis which compared the effects of romosozumab to placebo, teriparatide, and alendronate in postmenopausal osteoporosis treatment. The change in bone mineral density at the lumbar spine, total hip, and femoral neck significantly favoured romosozumab versus both placebo and active controls. Fracture rates after 24 months also significa...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.

Continue